Checkpoint Inhibitors

Goals

  • To learn about checkpoint inhibitors: what they are, recent history, impact on cancer care, how significant their revenues are to the industry, and how their use is expected to increase over time.

Early Findings

  • According to the National Cancer Institute, checkpoint inhibitors are "a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells." Additionally, they are usually described "as therapies that release the brakes on the immune system."
  • The New Yorker explains checkpoint inhibitors as drugs that "prevent tumor cells from impeding T-cell activity."
  • The Global Immune Checkpoint Inhibitors market equaled $10,540 million in 2017 and is forecast to equal $65,427 million by 2025, growing at a CAGR of 25.6%.
  • The Global Cancer Immunotherapy market equaled $42,584.18 million in 2017 and is forecast to equal $86,678.7 million by the end of 2027, growing at a CAGR of 7.5%.
  • As evidenced by the market sizes included above, the checkpoint inhibitor market is growing significantly faster than the immunotherapy market as a whole.
  • Checkpoint inhibitors have shown promise in treating and destroying cancers that do not respond to chemotherapy or radiation. Metastatic lung cancer, cancer that doesn't respond to chemotherapy, radiation, or any other therapy, can be cured by checkpoint inhibitors in some patients.
  • It is predicted that over 50% of cancer patients will receive checkpoint inhibitors in the near future.
Summary Of Our Early Findings Relevant To The Goals
  • Our first hour of research was able to provide some required information and touch on other required information. We defined checkpoint inhibitors. While we were unable to find specific revenues, we were able to find the global checkpoint inhibitor market size for 2017, the global immunotherapy (of which checkpoint inhibitors belong) market size, and the predicted market sizes for both markets that help show how significant checkpoint inhibitors are to immunotherapy.
  • Additionally, while we touched on the impact checkpoint inhibitors have on cancer care/treatment, we did not have time in our first hour of research to provide additional detailed information on this impact. We also did not have time in our first hour of research to provide the recent history of checkpoint inhibitors.
  • Please select one or more of the options provided in the proposed scoping section below.

Proposed next steps:

You need to be the project owner to select a next step.